|
Price: $43.3200
$1.16 
2.751%
|
| Day's High:
| $44.75
| Week Perf:
| -0.07 %
|
| Day's Low: |
$ 42.71 |
30 Day Perf: |
21.17 % |
| Volume (M): |
1,001 |
52 Wk High: |
$ 63.57 |
| Volume (M$): |
$ 43,359 |
52 Wk Avg: |
$47.73 |
| Open: |
$43.14 |
52 Wk Low: |
$31.28 |
|
|
| Market Capitalization (Millions $) |
5,100 |
| Shares
Outstanding (Millions) |
118 |
| Employees |
1,500 |
| Revenues (TTM) (Millions $) |
564 |
| Net Income (TTM) (Millions $) |
-248 |
| Cash Flow (TTM) (Millions $) |
47 |
| Capital Exp. (TTM) (Millions $) |
83 |
10x Genomics Inc
10x Genomics Inc.
is a life science technology company that specializes in developing and manufacturing next-generation sequencing platforms and associated software tools.
The company was founded in 2012 and is headquartered in Pleasanton, California.
The company's core technology is based on a droplet-based synthetic biology approach that enables the parallel analysis of thousands of individual cells or DNA molecules at the same time, greatly speeding up the pace of genomic research.
10x Genomics offers several products and services that leverage this technology, including single-cell and spatial gene expression solutions, immune profiling, and genome assembly.
10x Genomics' flagship product is the Chromium System, a high-throughput single-cell analysis platform that can process up to 10,000 cells in a single run.
The Chromium System enables researchers to generate high-quality gene expression data at a single-cell resolution, allowing for the identification and characterization of rare cell populations and the discovery of new biomarkers.
In addition to its research-focused offerings, 10x Genomics has also developed several clinical-grade products, including the Visium Spatial Gene Expression Solution, which enables spatial mapping of gene expression on tissue sections.
The company's products have been used in a wide range of applications, including cancer immunotherapy research, drug discovery, and agricultural genomics.
In terms of financials, 10x Genomics has experienced rapid growth since its founding, with reported revenues of $100 million in 2017, $245 million in 2018, and $375 million in 2019.
The company's stock is publicly traded on the NASDAQ stock exchange under the ticker symbol TXG.
Overall, 10x Genomics is a cutting-edge life science technology company that has developed innovative solutions for genomic research and analysis.
Its technology and products have the potential to transform the way we understand and treat complex diseases, making it a key player in the rapidly-evolving genomics market.
Company Address: 6230 Stoneridge Mall Road Pleasanton 94588 CA
Company Phone Number: 401-7300 Stock Exchange / Ticker: NASDAQ TXG
| TXG is expected to report next financial results on February 15, 2024. |
|
|
|
|
|
|
|
|
| Stock Performances by Major Competitors |
|
|
|
|
Cytek Biosciences Inc
Cytek Biosciences Inc (CTKB) has shown impressive growth in its stock value, gaining 12.39% over the past five trading days. Additionally, despite a challenging year, the company's stock has seen a significant increase of 66.55% compared to the previous year. Furthermore, Cytek Biosciences Inc's stock currently trades 28.9% above its 52-week low. Analyzing these financial results, it becomes evident that the company has managed to battle industry headwinds and achieve notable progress. However, it is crucial to consider the company's recent fiscal performance and other factors that may impact the company's future outlook.
Fiscal Performance:
For the fiscal period ending September 30, 2023, Cytek Biosciences Inc has recorded a shortfall per share of -$0.05, compared to a positive $0.01 per share a year earlier. This represents a decline from the preceding reporting season's shortfall of -$0.03 per share. Although the company has experienced a widening shortfall, it is important to note that revenue has increased significantly.
|
|
Talis Biomedical Corporation
The latest financial results reported by Talis Biomedical Corporation for the period ending September 30, 2023, paint a bleak picture. With a significant decline in revenue and expanding net deficits, the company has announced its intention to explore strategic alternatives to maximize shareholder value. This article will delve into the impact these results may have on the company's future prospects.
Dismal Revenue and Widening Deficit:
Talis Biomedical Corporation witnessed a staggering 82.412% decline in revenue compared to the same reporting period last year, earning only $0.14 million. This follows a 75.904% revenue drop from the previous reporting period, where the company generated $0.58 million. These figures indicate a concerning trend of declining sales.
|
|
Singular Genomics Systems Inc
The Laboratory Analytical Instruments company, Singular Genomics Systems Inc, reported limited revenue of only $0.462 million in the third quarter of 2023. Moreover, the company experienced a net loss of an alarming $-22.360 million in the same quarter, a significant deterioration compared to the previous year's deficit of $-23.790 million. Furthermore, inventories have declined to $13.4 million, indicating potential weakening future demand. These factors, coupled with other concerning indicators, suggest a bearish outlook for Singular Genomics Systems Inc.
Declining Inventories Reflect Lower Demand:
A critical aspect to assess a company's growth prospects lies in its inventory levels, which provide insight into future demand. Singular Genomics Systems Inc witnessed a decline in inventories to $13.4 million in the third quarter, compared to the previous quarter as well as the same period a year before. This reduction raises concerns about weakening demand and potential challenges the company may face in generating future revenue.
|
|
Illumina Inc
Illumina Inc, a Laboratory Analytical Instruments company, experienced a challenging third quarter in 2023, reporting a loss of $-4.77 per share. This marked an improvement from the previous year, where the loss per share was significantly higher at $-24.26.
Interestingly, while most companies in the Laboratory Analytical Instruments sector saw a decline in revenue, Illumina Inc managed to achieve a slight growth of 0.359%. The company's revenue reached $1.12 billion during the quarter, compared to $1.12 billion in the same period the previous year. However, there was a sequential decrease in revenue of -4.847% from $1.18 billion.
|
|
Astrotech Corp
Astrotech Corp is a company operating in the Laboratory Analytical Instruments sector that has experienced strong revenue growth in the first quarter of the 2024 earnings season. Despite this positive revenue increase of 1018.421% year on year to $0.43 million, the company also saw a significant increase in its deficit per share at $-1.79.
In comparison to the previous quarter, there was an increase in the deficit per share from $-1.44 and a revenue increase of 2.657% from $0.41 million. This suggests that Astrotech Corp is performing well relative to other companies in the same sector, as many have been affected by receding transactions and declining top-line figures.
|
| Per Share |
Current |
| Earnings (TTM) |
-2.13 $ |
| Revenues (TTM) |
4.79 $
|
| Cash Flow (TTM) |
0.4 $ |
| Cash |
3.03 $
|
| Book Value |
6.33 $
|
| Dividend (TTM) |
0 $ |
|
|
| Per Share |
|
| Earnings (TTM) |
-2.13 $
|
| Revenues (TTM) |
4.79 $ |
| Cash Flow (TTM) |
0.4 $ |
| Cash |
3.03 $
|
| Book Value |
6.33 $ |
| Dividend (TTM) |
0 $ |
|
|
|
|
